MX2012012905A - Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas. - Google Patents

Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas.

Info

Publication number
MX2012012905A
MX2012012905A MX2012012905A MX2012012905A MX2012012905A MX 2012012905 A MX2012012905 A MX 2012012905A MX 2012012905 A MX2012012905 A MX 2012012905A MX 2012012905 A MX2012012905 A MX 2012012905A MX 2012012905 A MX2012012905 A MX 2012012905A
Authority
MX
Mexico
Prior art keywords
treatment
diseases
hyperproliferative
angiogenic diseases
hydroxyalkyl
Prior art date
Application number
MX2012012905A
Other languages
English (en)
Inventor
Michael Haerter
Karl-Heinz Thierauch
Joachim Schuhmacher
Peter Ellinghaus
Hartmut Beck
Frank Suesmeier
Susanne Greschat-Schade
Kerstin Unterschemmann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MX2012012905A publication Critical patent/MX2012012905A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a derivados de 1-[3-(hidroxialquil) bencil]-IH-pirazol novedosos, a procedimientos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades y a su uso para la producción de medicamentos para el tratamiento yio la prevención de enfermedades, más particularmente para el tratamiento y/o la prevención de enfermedades hiperproliferativas y angiogénicas y para las enfermedades provocadas por la adaptación metabólica a estados hipóxicos. Dichos tratamientos pueden llevarse a cabo en forma de monoterapia o también en combinación con otros medicamentos o medidas terapéuticas adicionales.
MX2012012905A 2010-05-08 2011-05-03 Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas. MX2012012905A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004854 2010-05-08
PCT/EP2011/057019 WO2011141325A1 (de) 2010-05-08 2011-05-03 Hydroxyalkylbenzyl- pyrazole und ihre verwendung zur behandlung von hyperproliferativen und angiogenen erkrankungen

Publications (1)

Publication Number Publication Date
MX2012012905A true MX2012012905A (es) 2012-12-17

Family

ID=44243203

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012905A MX2012012905A (es) 2010-05-08 2011-05-03 Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas.

Country Status (12)

Country Link
EP (1) EP2569309A1 (es)
JP (1) JP2013530139A (es)
KR (1) KR20130108998A (es)
CN (1) CN103003266A (es)
AU (1) AU2011252222A1 (es)
BR (1) BR112012028652A2 (es)
CA (1) CA2798374A1 (es)
IL (1) IL222850A0 (es)
MX (1) MX2012012905A (es)
RU (1) RU2012152800A (es)
WO (1) WO2011141325A1 (es)
ZA (1) ZA201209298B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2888256A4 (en) * 2012-08-24 2016-02-17 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
NZ704799A (en) 2012-08-24 2018-06-29 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
EP2888253A4 (en) 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC MODULATORS OF HIF FACTOR ACTIVITY USED FOR THE TREATMENT OF DISEASES
ES2726648T3 (es) 2014-02-25 2019-10-08 Univ Texas Sales de moduladores heterocíclicos de la actividad del HIF para el tratamiento de enfermedades
CN107235873B (zh) * 2017-07-04 2018-11-06 中节能万润股份有限公司 一种美司钠的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2005030121A2 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
WO2008141731A2 (en) 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2356113B1 (de) * 2008-11-14 2015-01-07 Bayer Intellectual Property GmbH Heterocyclisch substituierte aryl-verbindungen als hif-inhibitoren
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds

Also Published As

Publication number Publication date
AU2011252222A1 (en) 2012-12-06
CN103003266A (zh) 2013-03-27
BR112012028652A2 (pt) 2016-08-09
ZA201209298B (en) 2014-05-28
KR20130108998A (ko) 2013-10-07
RU2012152800A (ru) 2014-06-20
IL222850A0 (en) 2012-12-31
CA2798374A1 (en) 2011-11-17
JP2013530139A (ja) 2013-07-25
EP2569309A1 (de) 2013-03-20
WO2011141325A1 (de) 2011-11-17

Similar Documents

Publication Publication Date Title
TN2012000531A1 (en) Substituted heterocyclyl benzyl pyrazoles, and use thereof
MY160004A (en) Heterocyclically substituted aryl compounds as hif inhibitors
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
AU2011328009A8 (en) Compounds and methods for treating pain
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
TN2014000320A1 (en) Substituted phenylimidazopyrazoles and use thereof
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX2012012905A (es) Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas.
MY150931A (en) Substituted oxazolidinones and their use
MX340585B (es) Derivados de 5-metil-1-(naftalen-2-il)-1h-pirazol y su uso en potencializar el efecto de los analgesicos opioides.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
JOP20110347B1 (ar) صوديوم 1h- بيرازول-5-أولات مستبدل
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
UA106500C2 (uk) Похідні піразолів, спосіб їх одержання та застосування в терапії
MX2009009332A (es) Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis.
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof